Cannabidiol in the acute phase of febrile infection-related epilepsy syndrome (FIRES).
CBD
cytokine
neuroinflammation
status epilepticus
Journal
Epilepsia open
ISSN: 2470-9239
Titre abrégé: Epilepsia Open
Pays: United States
ID NLM: 101692036
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
16
11
2022
accepted:
08
04
2023
medline:
5
6
2023
pubmed:
13
4
2023
entrez:
12
4
2023
Statut:
ppublish
Résumé
Febrile infection-related epilepsy syndrome (FIRES) is a prolonged refractory status epilepticus (SE) that develops among healthy individuals after a febrile infection. FIRES treatment is challenging due to its poor response to antiseizure medications (ASMs) and anesthetic drugs. The use of cannabidiol (CBD) as an adjunctive treatment has been suggested, albeit data about its role in the acute phase is lacking. This report describes the use of purified CBD in the acute phase of two pediatric cases of FIRES and their long-term outcome. Both children were treated with several ASMs, immunomodulators, anesthetics, and nonpharmacological treatment (ketogenic diet). CBD was administered, as an adjunctive treatment, through nasogastric tube about 30 days after onset. SE resolved within 3 days of reaching the target dose and both were seizure-free for 1 year after. Although it is difficult to define the extent to which each previous therapy contributed to recovery, in both cases CBD therapy was a turning point, reinforcing its potential role as add-on treatment in the acute phase of FIRES.
Identifiants
pubmed: 37042946
doi: 10.1002/epi4.12740
pmc: PMC10235155
doi:
Substances chimiques
Cannabidiol
19GBJ60SN5
Anesthetics
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
685-691Informations de copyright
© 2023 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Epilepsia Open. 2021 Jan 13;6(1):62-72
pubmed: 33681649
Dev Med Child Neurol. 2020 Aug;62(8):897-905
pubmed: 32372459
Neuropsychiatr Dis Treat. 2019 Jul 09;15:1897-1903
pubmed: 31371963
Epilepsia. 2018 Apr;59(4):745-752
pubmed: 29476535
Ann Neurol. 2014 Feb;75(2):178-85
pubmed: 24318290
Epilepsia. 2011 Nov;52(11):1956-65
pubmed: 21883180
Neurology. 2022 Mar 8;98(10):e1090-e1091
pubmed: 34937779
Epilepsia. 2018 Apr;59(4):739-744
pubmed: 29399791
Epilepsia Open. 2019 Mar 27;4(2):344-350
pubmed: 31168503
Front Pharmacol. 2021 Mar 03;12:637801
pubmed: 33746760
Epileptic Disord. 2020 Jan 1;22(S1):10-15
pubmed: 32053110
J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):820-2
pubmed: 25398790
Neurosci Lett. 2018 Feb 22;667:84-91
pubmed: 28011391
Ann Neurol. 2019 Apr;85(4):526-537
pubmed: 30779222
Epilepsia Open. 2023 Jun;8(2):685-691
pubmed: 37042946
Child Neurol Open. 2020 Dec 15;7:2329048X20979253
pubmed: 33403221
Epilepsia Open. 2023 May;8 Suppl 1:S110-S116
pubmed: 35434910
Sci Rep. 2016 Jan 21;6:19674
pubmed: 26790609
Brain Dev. 2023 May;45(5):293-299
pubmed: 36725381
Ann Clin Transl Neurol. 2020 Dec;7(12):2467-2474
pubmed: 33506622
Epilepsia. 2020 Jun;61(6):1090-1098
pubmed: 32452532
Drugs. 2019 Sep;79(13):1435-1454
pubmed: 31372958
Toxicology. 2021 Dec;464:153016
pubmed: 34740670
Neuropediatrics. 2012 Aug;43(4):209-16
pubmed: 22911482
J Child Neurol. 2017 Jan;32(1):35-40
pubmed: 27655472
Epilepsy Res. 2020 Nov;167:106454
pubmed: 32987244
Biomed J. 2020 Jun;43(3):205-210
pubmed: 32330681
Epilepsia. 2015 Aug;56(8):1246-51
pubmed: 26114620
Clin Pharmacol Drug Dev. 2019 Nov;8(8):1009-1031
pubmed: 30791225
Eur J Paediatr Neurol. 2019 Sep;23(5):749-754
pubmed: 31446001
Molecules. 2022 Aug 04;27(15):
pubmed: 35956911
Epilepsia. 2019 Mar;60(3):419-428
pubmed: 30740695
Epilepsy Behav Rep. 2022 Feb 22;18:100531
pubmed: 35356746
Ann Neurol. 2016 Dec;80(6):939-945
pubmed: 27770579
Epilepsia. 2021 Feb;62(2):303-324
pubmed: 33316111